Seeking Alpha
Editor's notes: A new HIV test could be a major growth engine for CEMI, says buysider Paul Nouri. Growing cash, NOLs, and a strong competitive position could make the company a steal.

Chembio (CEMI) is a diagnostic company with a focus on developing and marketing point of care tests. Since 2008, the company's revenues have grown significantly as it has penetrated international markets, developed new technology and worked with its U.S. partner, Alere (ALR), to gain share.

Despite the impressive run up in sales, stock performance has been disappointing over the past year. Up to March of this year, it looked as if the company's shares were on a roll (with the rest of the market). Then two events happened. First, the company reported its fourth quarter 2012 results on March 7. Despite sales in the quarter being 18% higher than in any other quarter...

Only subscribers can access this article, which is part of the PRO research library covering 3,778 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: